Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps.
Philippe GevaertStella E LeeRussell A SettipaneMartin WagenmannJérôme MsihidShahid SiddiquiScott NashJuby A Jacob-NaraAsif H KhanSiddhesh KamatChien-Chia ChuangPublished in: Clinical & translational immunology (2023)
Significantly, more patients achieved improvement from moderate-to-severe symptoms to no-to-mild symptoms with dupilumab than placebo, regardless of prior surgery or coexisting asthma. Improvement was observed as early as Week 2 and continued through to Week 52.
Keyphrases
- chronic rhinosinusitis
- atopic dermatitis
- end stage renal disease
- sleep quality
- ejection fraction
- newly diagnosed
- minimally invasive
- chronic obstructive pulmonary disease
- prognostic factors
- coronary artery bypass
- placebo controlled
- high intensity
- lung function
- patient reported outcomes
- acute coronary syndrome
- physical activity
- cystic fibrosis
- air pollution
- depressive symptoms
- open label
- study protocol
- patient reported